Research Keyword: CAR T-cell therapy

Clinical Mycology Today: Emerging Challenges and Opportunities

mycolabadmin

Fungal infections are becoming more common because of new medical treatments that suppress immune function, and some fungi are developing resistance to standard medications. However, exciting new antifungal drugs are in development that work in different ways and may be easier to use. The article discusses how doctors need better ways to identify patients at risk, design better clinical trials, and train more specialists to handle these increasingly complex fungal infections.

Read More »

Schizophyllum commune infection following chimeric antigen receptor T-cell therapy in a patient with lymphoma

mycolabadmin

A 71-year-old woman receiving CAR T-cell therapy for lymphoma developed a rare fungal lung infection caused by Schizophyllum commune six months after treatment. The infection presented similarly to other fungal diseases affecting the lungs and was diagnosed through bronchoscopy and fungal culture despite negative blood antibody tests. Standard antifungal medication (voriconazole) taken by mouth for four months completely resolved the infection, highlighting the need to consider rare fungi in patients receiving advanced cancer immunotherapies.

Read More »
Scroll to Top